Recent approaches that have investigated the role of synaptic loss in PSP and CBD aimed to better understand tauopathies by mapping synaptic density based on the affinity for a presynaptic vesicle glycoprotein (SV2A) [85,86]. The gene discussed is SV2A; the disease is supranuclear palsy, progressive, 1.